HYPR241220C5000
- 0.00
- 0.000.00%
Hyperfine Newsroom
Wells Fargo Maintains Hyperfine(HYPR.US) With Hold Rating, Maintains Target Price $1.2
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
B. Riley Adjusts Price Target on Hyperfine to $1.50 From $1.30, Maintains Buy Rating
Hyperfine Analyst Ratings
Jefferies Initiates Coverage On Hyperfine With Hold Rating, Announces Price Target of $1.25
Hyperfine Analyst Ratings
Hyperfine Analyst Ratings
B. Riley Lifts Hyperfine's Price Target to $3.50 From $2.50 After Higher-Than-Expected Q2 Results, Keeps Buy Rating
B.Riley Financial Reaffirms Their Buy Rating on Hyperfine (HYPR)
B.Riley Financial Remains a Buy on Hyperfine (HYPR)
B. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $2.5
Hyperfine (HYPR) Gets a Buy From B.Riley Financial
Hyperfine Analyst Ratings
B. Riley Securities Initiates Coverage On Hyperfine With Buy Rating, Announces Price Target of $3.5
Hyperfine Cut to Equal-Weight From Overweight by Wells Fargo
Hyperfine Price Target Cut to $2.40/Share From $8.00 by Wells Fargo
Hyperfine analyst ratings
Wells Fargo Downgrades Hyperfine to Equal-Weight, Lowers Price Target to $2.4
Evercore ISI Adjusts Hyperfine's Price Target to $5.50 From $7, Maintains Outperform Rating
Hyperfine Price Target Announced at $7.00/Share by Evercore ISI Group